services · Scoped per programme
Variant-informed target analysis
Assess how human genetic variation may affect target structure, binding-site context and drug-response hypotheses.
The challenge
Why this matters
Human genetic variation can influence pharmacokinetics, pharmacodynamics, target biology, pathway activity and safety-relevant mechanisms. In some programmes that evidence becomes important for target selection, patient stratification, clinical interpretation or regulatory review.
Sequence variation alone does not show a mechanism. A variant may alter a binding site, reshape local interactions, affect protein dynamics or change pathway behaviour in ways that matter for a specific compound or disease hypothesis.
What we deliver
What we do about it
Discovera combines structural bioinformatics, molecular modelling, biophysical simulation where appropriate and clinical genetics context to evaluate selected variants across target structure, dynamics and drug-target interaction hypotheses.
The output is a mechanistic report that maps variants onto structures, binding sites, functional regions and population-frequency data where available, identifying hypotheses to test and risks to monitor. It is a report for programme design, not a clinical prediction.
Our methodology
Four steps from variant map to mechanistic interpretation
- 01Variant mapping
Population-associated and disease-relevant variants are collected from sources such as gnomAD, ClinVar and PharmGKB, then mapped onto protein sequences, structures, binding sites and functional regions.
- 02Structural dynamics
Variants are evaluated for potential effects on local structure, pocket geometry, interaction networks, conformational stability and ligand-binding context.
- 03Functional interpretation
Variant positions are interpreted in relation to pathway biology, receptor signalling, regulatory annotations, known pharmacogenomic evidence and disease mechanism.
- 04Drug-target interaction hypotheses
For relevant variants we assess whether altered structure or local chemistry may affect ligand binding, selectivity or target-engagement hypotheses, and define which effects require experimental follow-up.
Your deliverable
What lands on your desk
Variant context report
Summary of relevant variants, source evidence, allele-frequency context and programme relevance.
Variant impact matrix
Structural and functional interpretation of variants mapped to protein regions, binding sites and known pharmacogenomic evidence.
Drug-target interaction analysis
Assessment of variants that may affect binding-site context, ligand interactions, selectivity or target-engagement hypotheses.
Clinical strategy considerations
Patient-stratification, monitoring, translational follow-up and regulatory considerations where supported by evidence.
Report support package
Technical report with data sources, methodology, assumptions, limitations and actionable recommendations.
Scientific foundation
The research behind the approach
This service builds on peer-reviewed work from the University of Verona ecosystem on variant effects in protein dynamics, stability, assembly, ligand recognition and protective or pathogenic mechanisms. These studies support the methodological basis for variant-informed structural interpretation.
Protein Dynamics & Catalysis
AADC enzyme flexibility and asymmetry mechanisms linking structure to genotype–phenotype relationships
Bisello et al., Protein Science 2023
Receptor Pharmacogenomics
Oxytocin receptor A218T variant shown to alter receptor stability and signaling, modulating drug response
Meyer et al., Mol. Psychiatry 2022
Protective Alleles for Drug Discovery
APOB truncating variant reducing LDL/CAD risk, informing therapeutic targeting by mimicking natural protection
Atherosclerosis Plus 2022
Additional applications: PH1/AGXT dimerization variants (Dindo et al., Biochimie 2016), BCKDK gain-of-function in metabolism (Maguolo et al., Genes 2022), GPCR modeling tools such as pyGOMoDo (Ribeiro & Giorgetti, Bioinformatics 2023), and ongoing AADC genotype–phenotype correlation studies (Bisello et al., FEBS Open Bio 2025).
Bring genetic variation into the decision earlier
Tell us the target, compound, disease question or variant concern behind the programme. We will reply with whether variant-informed analysis, DiscoveraVS or neither is the right route.